Manufacturing and Import Authorisations for Veterinary Medicines: Articles 88 and 90

Anyone who manufactures, finishes, tests, releases or imports veterinary medicines in the EU needs a manufacturing authorisation. Regulation (EU) 2019/6 defines the scope broadly, and the authorisation is tied to the site and forms named in it.

Which activities are covered

Under Article 88(1), a manufacturing authorisation is required for:

  • manufacturing veterinary medicinal products, even if only for export;
  • any part of manufacturing or finishing, including processing, packaging, labelling, storing, sterilising, testing or releasing for supply;
  • importing veterinary medicinal products.

Member States may exempt dividing up, repackaging or changing presentation when done solely for retail sale directly to the public. Where that exemption applies, each portion must carry a package leaflet, with batch number and expiry date clearly shown.

Granting and scope

  • The competent authority must inspect the manufacturing site before granting the authorisation (Article 90).
  • The authorisation applies only to the site and pharmaceutical forms specified.
  • Member States set the procedure, which must not take more than 90 days from receipt of the application; the clock is suspended while additional information is requested.
  • An authorisation may be granted subject to conditions, and suspended or revoked if they are not met.

Union-wide validity and recording

Manufacturing authorisations are valid throughout the Union and are recorded in the Union manufacturing and wholesale distribution database. This makes the public record a useful check on the status of your sites and your contract partners.

Practical considerations

  • Align the authorisation scope with actual operations before inspection, especially for new forms, new sites and testing laboratories.
  • Treat importation as a regulated manufacturing activity, with its own site, controls and release arrangements.
  • Link the authorisation to quality agreements and to the current EU GMP requirements for veterinary medicines.

Inspection and quality system links

Inspectors look for consistency between the authorisation, the actual operations on site and the quality system. Typical findings include activities carried out at a site or for a pharmaceutical form not named in the authorisation, outdated contract laboratories and unclear responsibilities between the importer and the third-country manufacturer.

Maintain a simple register that maps each activity and product to the relevant authorisation, quality agreement and responsible person. Update it whenever a change is planned, and ask whether the change requires notification or a variation of the authorisation before it is implemented.

Key takeaways

  • Import, testing, storage and release are all covered activities.
  • The authorisation is specific to site and pharmaceutical forms.
  • Expect a pre-grant inspection and a procedure of up to 90 days at national level.
  • Authorisations are valid Union-wide and publicly recorded.
  • Keep scope, quality agreements and actual practice aligned at all times.

How PQRA helps

PQRA helps veterinary manufacturers and importers prepare authorisation applications, check scope against real operations, and align quality systems and agreements with the requirements that inspectors will test.

Contact PQRA to discuss manufacturing and import authorisations for veterinary medicines.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *